PR86685

BOAO, China, Nov. 18, 2020 /PRNewswire=KYODO JBN/ --

On November 14th, 2020, Bo'ao Winhealth Rare Disease Medical Center was

officially launched, jointly built by Hainan Bo'ao International Medical

Tourism Pilot Zone Administration, Winhealth Pharma Group (HK) and Bo'ao

Worldlight Hospital.

Main leaders of Hainan Provincial Health Commission, Hainan Medical Products

Administration, Hainan Bo'ao International Medical Tourism Pilot Zone

Administration, Winhealth Pharma Group (HK), Bo'ao worldlight hospital, etc

attended the ceremony and delivered speeches. Authoritative experts on rare

diseases from major Chinese provinces and cities, representatives from China

biggest patient groups like ICF and CORD and representatives from

multi-national pharmaceutical companies attended as well. Besides, Winhealth

and Ethypharm completed the signing ceremony of orphan drug Orphacol®.

Since acquiring the authorization from Lecheng Administration, the center has

established cooperation with various experts and institutes for rare diseases,

patient groups and various domestic and oversea pharmaceutical companies. With

the mission of "To become the most comprehensive and advanced rare disease

medical center with the most advanced medical services in China, Southeast Asia

and other surrounding areas", the center will actively explore successful

operation models to bridge to future national rare disease medical center. The

functions of the center include introducing advanced rare disease medicines and

devices, providing high-end medical services, cooperating with manufacturers,

insurance companies and other stakeholders to solve affordability issues,

undertaking real-world studies in the short term, and other clinical trials in

the future to support registration of overseas rare disease products in China,

hosting and participating in domestic and oversea academic activities and

patient group activities to facilitate the improvement of disease awareness and

the level of diagnosis and treatment for rare diseases.

Forward-looking statements

This announcement contains forward-looking statements, reflecting the current

beliefs and expectations of Winhealth Pharma Group (HK). These statements are

based on expectations and assumptions about the current available information

and are subject to known and unknown risks and uncertainties that may cause

actual results to differ significantly from such statements. We have no

willingness or obligation to update or modify any forward-looking statements,

whether as a result of additional information, future events or other circumstances.

SOURCE  Winhealth Pharma Group HK